共 50 条
- [31] Efficacy and safety of rifaximin in the treatment of mild-moderate Crohn's disease: Results of an open-label pilot studyGASTROENTEROLOGY, 2005, 128 (04) : A579 - A579Kornbluth, AHunt, MGeorge, JLatzman, GRochester, JFried-Boxt, ELegnani, P
- [32] Long-Term Safety and Efficacy of Certolizumab Pegol Therapy in Patients With Moderate to Severe Crohn's Disease: 5-Year ResultsAMERICAN JOURNAL OF GASTROENTEROLOGY, 2015, 110 : S774 - S775Ptak, TheadoreYounes, ZiadShafran, IraLee, ScottMiner, Philip B.Kayhan, CemKosutic, GordanaCoarse, JasonHasan, IramSpearman, MarshallSandborn, William J.
- [33] Safety of adalimumab in children and adolescents with moderate-to-severe Crohn's disease: interim results of the CAPE registryJOURNAL OF CROHNS & COLITIS, 2018, 12 : S35 - S35Turner, D.Koletzko, S.Winter, H.Baldassano, R.Dubinsky, M.Faubion, W.Hyams, J.Kugathasan, S.Rosh, J.Escher, J.Griffiths, A.Kierkus, J.Russell, R.Heap, G.Arikan, D.Kuehnl, V.Petersson, J.Robinson, A.Ruemmele, F.
- [34] Efficacy and Safety of Oral Tofacitinib for Maintenance Therapy in Patients With Moderate to Severe Crohn's Disease: Results of a Phase 2B Randomized Placebo-Controlled TrialGASTROENTEROLOGY, 2016, 150 (04) : S183 - S183D'Haens, Geert R.Panaccione, RemoHiggins, PeterColombel, Jean-FredericFeagan, Brian G.Moscariello, MicheleChan, GaryHealey, Paul J.Niezychowski, WojciechWang, WenjinMarren, AmyMaller, Eric
- [35] EFFICACY & SAFETY OF DOSE ADJUSTMENT & DELAYED RESPONSE TO USTEKINUMAB IN MODERATE-SEVERE CROHN'S DISEASE PATIENTS: RESULTS FROM IM-UNITI MAINTENANCE STUDYGUT, 2017, 66 : A23 - A23Sands, B.Gasink, C.Jacobstein, D.Gao, L.Johanns, J.Szapary, P.Colombel, J.Targan, S.Ghosh, S.Sandborn, W.
- [36] Safety and Efficacy of Oral Octreotide in Acromegaly: Results of a Multicenter Phase III TrialJOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2015, 100 (04): : 1699 - 1708Melmed, ShlomoPopovic, VeraBidlingmaier, MartinMercado, Moisesvan der Lely, Aart JanBiermasz, NienkeBolanowski, MarekCoculescu, MihailSchopohl, JochenRacz, KarolyGlaser, BenjaminGoth, MiklosGreenman, YonaTrainer, PeterMezosi, EmeseShimon, IlanGiustina, AndreaKorbonits, MartaBronstein, Marcello D.Kleinberg, DavidTeichman, SamGliko-Kabir, IritMamluk, RoniHaviv, AsiStrasburger, Christian
- [37] Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Crohn's DiseaseGASTROENTEROLOGY, 2022, 162 (02) : 495 - 508Sands, Bruce E.Peyrin-Biroulet, LaurentKierkus, JaroslawHiggins, Peter D. R.Fischer, MonikaJairath, VipulHirai, FumihitoD'Haens, GeertBelin, Ruth M.Miller, DebraGomez-Valderas, ElisaNaegeli, April N.Tuttle, Jay L.Pollack, Paul F.Sandborn, William J.
- [38] Efficacy and safety of tralokinumab in adolescents with moderate-to-severe atopic dermatitis: results of the phase III ECZTRA 6 trialBRITISH JOURNAL OF DERMATOLOGY, 2022, 187 (03) : E90 - E91Paller, AmyBlauvelt, AndrewSoong, WeilyImafuku, ShinichiHong, Chih-HoSchuttelaar, Marie L. A.Amoudruz, PetraKurbasic, AzraSoldbro, LiseLophaven, KatjaCork, MichaelBewley, AnthonySimpson, Eric L.
- [39] Efficacy and safety of tralokinumab in adolescents with moderate-to-severe atopic dermatitis: results of the phase III ECZTRA 6 trialBRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (04) : E145 - E146Paller, A.Blauvelt, A.Soong, W.Imafuku, S.Hong, C.Schuttelaar, M. L. A.Amoudruz, P.Kurbasic, A.Soldbro, L.Lophaven, K.Schneider, S.Cork, M.Bewley, A.Simpson, E. L.
- [40] Efficacy, Safety, Patient Experience, and Tolerability of Risankizumab Administered by On-Body Injector for Moderate to Severe Crohn's DiseaseADVANCES IN THERAPY, 2023, 40 (05) : 2311 - 2325Loftus, Edward V.Griffith, JennyNeimark, EzequielSong, AlexandraWallace, KoriNannapaneni, SujaniZhou, JiByrne, RachelKligys, KristinaPang, YinuoLiao, XiaomeiKalabic, JasminaDubinsky, Marla